ATE522537T1 - (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis - Google Patents

(e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis

Info

Publication number
ATE522537T1
ATE522537T1 AT09701170T AT09701170T ATE522537T1 AT E522537 T1 ATE522537 T1 AT E522537T1 AT 09701170 T AT09701170 T AT 09701170T AT 09701170 T AT09701170 T AT 09701170T AT E522537 T1 ATE522537 T1 AT E522537T1
Authority
AT
Austria
Prior art keywords
treatment
propylü
phenylü
methylsulfone
cyclohepten
Prior art date
Application number
AT09701170T
Other languages
English (en)
Inventor
Matthew Carson
Michael Coghlan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE522537T1 publication Critical patent/ATE522537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT09701170T 2008-01-11 2009-01-08 (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis ATE522537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2052008P 2008-01-11 2008-01-11
PCT/US2009/030374 WO2009089312A1 (en) 2008-01-11 2009-01-08 (e)-n-{3- [1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] cycl0hepten-5ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid

Publications (1)

Publication Number Publication Date
ATE522537T1 true ATE522537T1 (de) 2011-09-15

Family

ID=40456776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09701170T ATE522537T1 (de) 2008-01-11 2009-01-08 (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis

Country Status (13)

Country Link
US (1) US8101761B2 (de)
EP (1) EP2231676B1 (de)
JP (1) JP2011525474A (de)
KR (1) KR101237296B1 (de)
CN (1) CN101910179B (de)
AT (1) ATE522537T1 (de)
AU (1) AU2009204155A1 (de)
BR (1) BRPI0906945A2 (de)
CA (1) CA2711885A1 (de)
EA (1) EA017288B1 (de)
ES (1) ES2370148T3 (de)
MX (1) MX2010007607A (de)
WO (1) WO2009089312A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011081173A1 (ja) * 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3730258A1 (de) 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
JPH01161245A (ja) 1987-12-18 1989-06-23 Canon Inc 電子写真感光体
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5093210A (en) 1989-06-30 1992-03-03 Ricoh Company, Ltd. Electroluminescent device
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
EP1154997A4 (de) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc Pharmazeutisch aktive verbindungen und ein verfahren zu ihrer herstellung
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
ES2308296T3 (es) * 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
KR20090020694A (ko) 2006-07-14 2009-02-26 일라이 릴리 앤드 캄파니 글루코코르티코이드 수용체 조절제 및 이의 사용 방법

Also Published As

Publication number Publication date
WO2009089312A1 (en) 2009-07-16
US8101761B2 (en) 2012-01-24
EP2231676B1 (de) 2011-08-31
MX2010007607A (es) 2010-08-23
EA201070844A1 (ru) 2011-02-28
US20100280062A1 (en) 2010-11-04
BRPI0906945A2 (pt) 2015-07-14
CN101910179B (zh) 2013-06-19
JP2011525474A (ja) 2011-09-22
AU2009204155A1 (en) 2009-07-16
CN101910179A (zh) 2010-12-08
EA017288B1 (ru) 2012-11-30
EP2231676A1 (de) 2010-09-29
KR101237296B1 (ko) 2013-03-04
CA2711885A1 (en) 2009-07-16
KR20100090808A (ko) 2010-08-17
AU2009204155A8 (en) 2010-07-08
ES2370148T3 (es) 2011-12-13

Similar Documents

Publication Publication Date Title
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
IN2012DN06720A (de)
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PH12014500386A1 (en) Combination treatment for hepatitis c
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MX385898B (es) Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
UA112420C2 (uk) Інгібітори апоптозу та їх застосування
PH12012501389A1 (en) Hedgehog inhibitors
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties